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Summary 
 
Objectives: To detail and put into perspective safety of hexaminolevulinate blue light 
cystoscopy (HAL-BLC), including repeated use, based on combined data of 
controlled trials used for registration of HAL and post-marketing experience. 
Methods: Safety data of two randomized comparative studies (group 1) and four 
within patient control studies (group 2) were combined. Post marketing data from 
>200,000 patients were analyzed.  
Results: In group 1, 533 patients  were examined with HAL-BLC and 499 with white 
light (WL) cystoscopy. In group 2, 791 patients were examined with both WL and 
HAL-BLC. Between 73% and 93% of these patients had concomitant diseases. 
Between 41% and 58% of patients had at least one adverse event (AE), although 
predominantly mild to moderate. The majority was considered as not related to HAL-
BLC and reported in the urinary tract. No SAEs were considered definitely related to 
HAL-BLC, but in 6 patients serious AEs were of an uncertain relationship. Four 
possibly related hypersensitivity reactions have been reported. Repeated use did not 
reveal additional toxicity, also supported by data from three European centers. 
Conclusions: This combined and detailed analysis of patients from 6 HAL-BLC 
studies with very comparable criteria shows that HAL-BLC is safe and poses very 
little additional risks other than expected for WL cystoscopy for bladder tumor 
resection in this specific patient population. This is supported by 9 years of post 
marketing experience. Repeated use also seems safe.  
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Introduction 
 
There have been only few new developments in the diagnosis and treatment of 
bladder cancer in recent decades. For example, in the treatment of non muscle-
invasive bladder cancer (NMIBC) Bacille Calmette-Guérin (BCG) was registered in 
the mid eighties. If therapy was very effective this would not be a major issue. 
However, recurrence rates in NMIBC are as high as 80% in high risk patients after 
some years, thus creating an urgency to improve management [1]. 
In the last decade blue light cystoscopy (BLC) has become standard of practice in 
many centres. BLC is done with hexaminolevulinate (HAL), which has been 
registered for this indication. HAL blue light cystoscopy (BLC) has proven to detect 
more bladder tumours, enabling a better tumour resection and better patient 
management. These effects result in a lower short term and long term recurrence 
rate of NMIBC [2-10]. A recent systemic review showed that 20% more patients with 
papillary tumors were detected, and 39% more CIS patients [2]. This resulted in less 
residual tumor (odds ratio 0.28) and a higher recurrence free survival (p=0.00002). 
Based on the reduction in long term recurrence rate [10] the registered indication of 
this drug changed from a pure detection tool to a drug that improves diagnosis and 
management of bladder cancer patients. The European Association of Urology (EAU) 
guideline recommends BLC in certain cases of (suspected) NMIBC [11]. In all, the 
effectiveness of HAL-BLC is clearly proven. 
Safety of HAL-BLC has been registered in all studies and BLC with HAL is 
considered safe and well tolerated. Some of these data have also been reported in 
the publications of these studies [3-9]. Since a favorable safety profile is an additional 
reason to embrace on a new drug or technique when improved effectiveness is 
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proven, this report specifically addresses the safety of HAL-BLC, including repeated 
use. 
This safety summary provides a review of detailed safety data collected in 
6 controlled clinical trials conducted with HAL powder for solution, which were the 
basis for the FDA approval 2010. Information from post-marketing experience is also 
presented. 
 
Patients and Methods  
 
Six controlled studies were used for this safety analyses and review. Details and 
results of these studies have been published before [3-9]. For all centers in these 6 
studies Ethics Committee approval was obtained and for all patients informed 
consent was obtained. Patient selection and treatment is very similar in all 6 studies. 
All studies used a single dose HAL 8-mM solution. Cystoscopy was done with the 
Karl Storz PDD D-light System. In all studies patients had a resection of papillary 
tumors or biopsies of suspicious area’s seen during white light (WL) or BLC. 
Four studies were within patient control studies (B201/00, B301/01, B302/01, 
B303/01), so in these studies all patients had HAL-BLC as well as WL cystoscopy. 
Studies B304/04 and B305/04 were randomized comparative studies, where patients 
were randomized to have the inspection and transurethral resection of a tumor 
(TURB) with WL, or HAL-BLC after WL.  
Because the six controlled clinical studies were very comparable, safety data were 
combined to study the safety profile of HAL-BLC in detail in this patient population. 
AEs definitions and description of baseline voiding were the same throughout the six 
studies. AEs were assessed from the time of HAL instillation until exit from the study. 
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Treatment-emergent adverse events (TEAEs) were defined as those events that 
occurred or worsened after exposure had begun. For patients in studies B305/04 and 
B304/04 who were randomized to the standard cystoscopy arms, TEAEs were events 
that occurred or worsened after the initiation of the standard cystoscopy procedure. 
AEs considered by the investigator to be related to HAL-BLC with a high degree of 
certainty or AEs where a relationship to HAL-BLC could not be ruled out are 
presented together as “related AEs.”  In the 305 extension study, thirty-nine out of 
551 participants (both in the BLC and in the WL group) had multiple HAL instillations 
after the initial study period. Data on possible anaphylactic reactions with repeated 
use was collected retrospectively. Postmarketing data from the product approved in 
2004 was also analysed.  
 
Results 
 
Efficacy 
As mentioned above, results of these 6 studies have been published before [3-9]. In 
short, all 6 studies showed significant increased detection rate with HAL-BLC, 
especially for CIS. Two studies also looked at recurrence rate as endpoint. Both 
studies showed an advantage for patients treated with HAL-BLC [3,4]. 
 
Safety 
The studies combined for the safety analysis have been grouped as follows: in group 
1 patients are included who received HAL-BLC (n=533) or WL (n=499) cystoscopy in 
studies B305/04 and B304/04. In group 2, 791 patients are included from the 4 older 
studies (B201/00, B301/01, B302/01, B303/01) in which patients had HAL-BLC after 
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WL cystoscopy during the same procedure and anesthesia. In group 1 the median 
age of the WL study group was 69.5, compared to 69.0 in the HAL-BLC group. In 
group 2 median age was 68.5. Patients in all studies were primarily white and the 
male female ratio was 3.2:1.  The patient population appeared homogenous across 
all six studies. Although the majority of patients had recurrent tumors, most had not 
received intravesical therapy before. 
As expected in a group of bladder cancer patients with advanced age, multiple co 
morbidities and concomitant medications were noted. In group 1, 86.8% of patients in 
the HAL-BLC study group and 73.3% of patients in the WL study group suffered from 
ongoing diseases, as compared with 93% of  patients in group 2. Baseline bladder 
symptoms, noted and registered at study entry, are shown in table 1. 
The safety evaluations that were performed in each of the six studies are listed in 
table 2. Data from individual studies were pooled to create integrated data sets for 
each of the data domains. 
An overview of results in the different groups is presented below. In table 3 the 
number of AEs is listed, whether the AEs are considered related, the number of AEs 
leading to treatment discontinuation, the number of SAEs and finally the number of 
deaths occurring during the study period. AEs per body system are detailed per 
degree of severity in tables 4 (HAL-BLC versus WL in group 1) and 5 (group 2). As 
expected, the most frequently involved body system in patients treated for bladder 
cancer is the urinary tract. The second most frequently involved body organ system 
was the gastrointestinal tract. AEs based on laboratory changes were rare, usually 
mild and none was considered related to HAL-BLC. Also no unexpected findings or 
adverse trends were apparent in vital signs or physical examination findings after 
treatment with HAL-BLC. No trends for increased toxicity have been noted in patients 
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whose instillation time exceeded the 1-hour period in the labeling. Mean HAL 
retention time was 88.4 minutes (range: 4.0 to 360.0 minutes), and exceeded 180 
minutes in 31 patients (table 6). 
No SAEs were considered definitively related to HAL-BLC in any clinical study. 
However, 8 SAEs observed in 6 patients were of an uncertain relationship to HAL-
BLC. Treatment discontinuation due to an AE was reported in 12 (0.9%) of the total 
of 1,324 patients. In group 1 eight BLC patients and one WL-cystoscopy patient were 
withdrawn from study participation because of an AE (considered all serious per 
protocol), none of which were considered to be related to HAL or WL exposure. In 
group 2, 3 patients were withdrawn from study participation because of an SAE. Two 
of these SAEs, in 1 patient, had an uncertain relationship to HAL exposure. 
For this locally administered product, no apparent drug-drug, drug-food, or 
drug-disease interactions were observed. 
Overall, 21 patients died in these 6 studies (table 3). No deaths were attributable to 
HAL-BLC.  
Repeated use was studied in the long term follow up of controlled trial B305/04 
(B305/E10). In the 4.5 years of follow up 29 of 128 European patients randomized to 
HAL-BLC received repeated HAL from commercial source at a repeat TURB. 
Thirteen patients had 1 additional TURB with HAL, 8 patients 2 additional HAL-
TURBs and 8 patients underwent ≥3 additional TURBs with HAL. Of the 131 
European patients in the WL group, 15 patients underwent 1 additional HAL-TURB, 4 
patients underwent 2 additional HA-TURBs and 6 patients underwent ≥3 additional 
HAL-TURBs. In total 39 patients were exposed to HAL at least twice during the study 
period. All files were checked retrospectively, and no adverse events suggesting 
anaphylaxis were found.  
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Comment 
 
AE’s into perspective. Although a summary of the AEs in the six individual studies 
has been presented in the respective publications [3-9], this detailed analysis makes 
it possible to put the AEs into the perspective of symptoms seen in bladder cancer 
and this specific older patient cohort. NMIBC is associated with hematuria in 80% to 
90% of patients [12-14]. Other less frequent signs are urinary frequency, dysuria and 
pain, and a range of other renal or urinary tract related problems. This is confirmed 
by data collected at study entry on bladder symptoms, before any manipulation had 
taken place. As can be seen in table 1, already 20% to 30% of patients have 
symptoms of the urinary tract at presentation. Another potential confounder in 
bladder cancer patients, which are older and often still smoking, is frequent 
competing co morbidities and concomitant medication. Indeed, nearly all patients 
included in this clinical program used a number of concomitant medications. These 
presenting symptoms and symptoms due to co morbidities should be distinguished 
from symptoms due to diagnosis, treatment and surveillance of bladder cancer, since 
obviously invasive procedures like cystoscopy, bladder biopsy, TURB and 
cauterization can cause similar symptoms. Although this is daily practice for any 
urologist, literature on quantitative analysis of typical complications occurring after 
cystoscopy with rigid scopes and biopsies or TURB are very sparse. The 
complications after flexible cystoscopy are better reported, and even flexible 
cystoscopy is reported to cause urgency and increased voiding frequency in 35% to 
40% of patients, and complaints of pain are reported  in 20% to 50% of patients 
[16,17]. Compared to our study, where rigid cystoscopy and TUR are applied, 
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procedural pain  and other urinary disorders and are found in approximately 5% and 
25% after HAL-BLC and  WL (table 4), and in 11.9% and 33.6% in those patients 
were HAL-BLC and WL were combined (table 5). Also other symptoms in our study 
are comparable or less as reported in literature. The frequency of urinary tract 
infections in our study is comparable to that after cystoscopy only [16-19]. Our overall 
frequency of hematuria after cystoscopy and TURB was 13.7%, compared to 
reported gross hematuria after flexible cystoscopy in 19% [17]. In all, since symptoms 
after rigid cystoscopy are reported twice as frequent compared to flexible cystoscopy 
[20], this puts symptoms in our studies in a positive perspective, having used rigid 
instruments in all studies. 
 
Type of AE’s and relation to the procedure. Most frequent AEs were renal and urinary 
disorders as expected [21], followed by gastro-intestinal AEs, procedural pain and 
urinary tract infection. Type and frequency of AEs were comparable between HAL-
BLC and WL cystoscopy in the two randomized studies and more frequently reported 
when BLC and WL cystoscopy were combined. Most of these AEs were mild to 
moderate. In patients receiving HAL-BLC, 79.8% of side effects had an onset during 
or after the cystoscopic examination and were unrelated to HAL-BLC, which is given 
more than one hour earlier. Similarly, in the WL study group, 87.2% AEs occurred 
during or after the cystoscopic examination. Overall, HAL instillation was associated 
with a low incidence of AEs that were considered by the investigator to be related to 
the study product (table 3). The percentage of SAEs was somewhat different 
between groups. The WL group in group 1 was in between these groups. SAEs were 
uncommon and none were definitely related to HAL-BLC. Treatment discontinuation 
due to an AE was also uncommon (0.9%) and not considered to be related to HAL 
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exposure, except two AEs in one patient where the relationship with HAL-BLC was 
considered uncertain. Overall, 21 patients died in these 6 studies which was 
expected in view of the population of elderly patients with multiple concomitant 
diseases. 
In all, when compared with the AE data in the WL study group, and considering 
baseline bladder cancer symptoms, concomitant disorders and discomfort due to the 
treatment, the analysis of the AE data in the HAL-BLC study group does not indicate 
significant risk beyond the current standard of care. The difference between group 1 
and group 2 is likely due to the fact that in the initial 4 studies patients had a WL 
cystoscopy followed by BLC. This results in an overall longer procedural time. 
 
BLC and concomitant disorders. Although there was a high prevalence of 
cardiovascular disease in the studied population (51.4% of HAL-BLC patients and 
47.1% WL-cystoscopy patients presented with ongoing vascular disorders and 30.8% 
of HAL-BLC and 27.1% WL-cystoscopy with ongoing cardiac disorders at baseline), 
there were no findings to indicate that HAL-BLC contributed to cardiovascular risk in 
individual patients.  
With regard to laboratory changes these were uncommon and predominantly mild. 
An increase in white blood cell counts might very well be a sign of urinary tract 
infection due to the procedure or even a reactive rise due to the procedure itself. 
Anemia obviously can be secondary to some bleeding after TURB. Slight decreases 
in hemoglobin may also be caused by an increased plasma volume in patients who 
were fasting and slightly dehydrated before the procedure and were rehydrated after 
the procedure. Although reported in other studies [22], we found no relationship 
between demographic factors and AEs. Finally the absence of increased toxicity in 
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case of higher or longer exposure to the drug and the safety profile in the post 
marketing period confirms the safety profile of HAL-BLC.  
 
Repeated use. An interesting issue is the repeated use of HAL. Repeated use of HAL 
can be expected and is done because of the fact that NMIBC frequently recurs, with 
subsequent repeated TURB’s. Prospective information on this issue is not available, 
but it has been studied retrospectively in 39 European patients in the long term follow 
up study B305/E10 where no adverse events suggesting anaphylaxis were found. 
Additionally, collection of data from 3 hospitals which have used HAL repeatedly 
(University Hospital, Tübingen, Germany, University Hospital, Regensburg, Germany 
and Guy’s Hospital, London, UK), showed no anaphylactic reactions via the post 
marketing reporting system (personal communication). The system contains data on 
917 patients, 210 (23%) of which had more than one, and 70 (8%) had more than 
two and up to six instillations of HAL during diagnosis and follow up of their bladder 
cancer. Finally, postmarketing experience reflects the experience in more than 
200,000 procedures with HAL-BLC over an 9 year period in 28 European countries 
and now in the USA. Between September 17, 2004 and June 12, 2013, there were a 
total of 27 reports of adverse drug reactions that have been received by the 
Marketing Authorization Holders. For two reported anaphylactoid reactions and two 
other cases of possible hypersensitivity reactions, a causal role of HAL-BLC could 
not be ruled out. Both reported anaphylactic reactions were in patients that had their 
first HAL instillation. The first report was in a 69 year old male. Five hours after the 
instillation, which had a 3 hours retention time, he experienced a fall in blood 
pressure, urticaria, chest pressure, swelling of the throat and atrial fibrillation. His 
serum tryptase (a marker of mast cell activation) increased 9 times, and later his skin 
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test was positive to HAL in duplicate. The mechanism remains uncertain, but it was 
reported to be likely a non IgE mediated allergic reaction caused by HAL [23]. A 
second event was a spontaneous report of an anaphylactoid shock in a 71 year old 
male. Within 2 minutes, hypotension and exanthema developed, with a subsequent 
coronary event due to the hypotension. He had a negative IgE enzyme immunoassay 
test to concomitant ATB, and his serum tryptase was normal, although done 5 days 
later. Whether this reaction was due to HAL-BLC or anesthetic medication remains 
unclear. The other reported adverse reactions were attributed to manifestations of 
underlying diseases or procedural complications.  
 
Limitations. A limitation of this study might be that data from six individual trials were 
combined. However, patient selection, characteristics and treatment, including the 
HAL-BLC procedure, were very similar throughout the six studies. Also, registration 
and definition of AEs remained the same. Indeed, the six individual datasets showed 
comparable adverse event spectra. Laboratory changes, vital signs and physical 
examination were not registered in all trials, but since they were uncommon and 
predominantly mild, it seems unlikely that more data would have given another 
spectrum of abnormalities.  
 
Conclusion 
 
In addition to the already published safety data of the six individual studies, the 
detailed analysis on safety of this large combined data set, enhanced by 8 years of 
post marketing experience, shows that  HAL-BLC is safe and well tolerated and 
poses very little additional risks in patients with known or suspected bladder cancer. 
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There were no signs that HAL-BLC contributed to the frequency or severity of AEs, 
other than what could be expected for WL cystoscopy, for TURB procedures and in 
this patient population. Except for  4 possible  cases of hypersensitivity reactions , no 
particular clusters of any particular post marketing reactions have been received. 
Repeated use also seems safe. On the other hand there is little discussion on the 
improved patient’s outcome after HAL TURB. This suggests a positive medical risk 
benefit ratio, which might stand up to other strategies to improve patient’s outcome 
with intravesical drug therapy. 
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 Table 1: Bladder symptoms at study entry in the safety set, when recorded. 
 
Group 1 Group 2  
HAL (n=533) 
n (%) 
WL (n=499) 
n (%) 
HAL (n=791) 
n (%) 
Hematuria 
Yes 48 (9.0%) 34 (6.8%) 134 (16.9%) 
No 372 (69.8%) 346 (69.3%) 655 (82.8%) 
Missing 0 (0.0%) 0 (0.0%) 2 (0.3%) 
Painful urination 
Yes 21 (3.9%) 17 (3.4%) 60 (7.6%) 
No 399 (74.9%) 363 (72.7%) 729 (92.2%) 
Missing 0 (0.0%) 0 (0.0%) 2 (0.3%) 
Frequent Urination or the Urge to Urinate, but without Results 
Yes 45 (8.4%) 46 (9.2%) 158 (20.0%) 
No 374 (70.2%) 334 (66.9%) 631 (79.8%) 
Missing 1 (0.2%) 0 (0.0%) 2 (0.3%) 
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Table 2. Safety evaluations performed per study 
 
Evaluations B201/00 B301/01 B302/01 B303/01 B304/04 B305/04 
Adverse events* X X X X X X 
Hematology and 
biochemistry† X X X    
Vital signs‡  X X X  X 
Physical examination‡  X X X  X 
Concomitant 
medications§ X X X X X X 
* Adverse events were monitored throughout the study. 
† Blood samples were collected before Hexvix instillation and at 24 hours after. 
‡ Evaluations were performed before Hexvix instillation and at 24 hours after. 
§ Concomitant medications were monitored and recorded throughout the follow-
up phase of each study. 
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Table 3: Overview of AEs experienced in the 6 controlled studies (safety set) 
 
Group 1 Group 2 
 
HAL 
N = 533 
WL 
N = 499 
HAL 
N = 791 
Total number of unique AEs 599 494 1,181 
Patients with at least one AE (n [%]) 232 
(43.5%) 
204 
(40.9%) 457 (57.8%) 
    
Total number of unique related 
AEs§ 56 1 232 
Patients with at least one related AE 
(n [%]) 38 (7.1%) 1 (0.2%) 123 (15.5%) 
    
Total number of unique AEs leading 
to discontinuation 8 1 4 
Patients with at least one AE 
leading to discontinuation (n [%]) 8 (1.5%) 1 (0.2%) 3 (0.4%) 
    
Total number of unique SAEs 63 47 57 
Patients with at least one SAE (n 
[%]) 51 (9.6%) 36 (7.2%) 47 (5.9%) 
    
Deaths occurring during the study 
period║ 10 (1.9%) 4 (0.8%) 7 (0.9%) 
Note: Patients with multiple AEs under one preferred term or body system are 
counted only once in the most severe category for that preferred term or body 
system.  If one event is related to exposure and another is not related, the related AE 
is counted. 
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Table 4. Summary of most frequent AEs by severity in group 1 
 
HAL, N = 533 WL, N = 499 
MedDRA Body 
System 
Preferred Term 
Mild 
n (%) 
Moderat
e, n (%) 
Seve
re, n 
(%) 
Sum 
n (%) 
Mild 
n (%) 
Modera
te, n %) 
Sever
e, 
n(%) 
Sum 
n (%) 
Total number of 
unique AEs occurring 
in at least 1% of the 
safety set across 
studies 
201 145 15 361 176 113 5 294 
Patients with at least 
one AE  
77 
(14.4%
) 
87 
(16.3%) 
15 
(2.8
%) 
179 
(33.6%
) 
84 
(16.8%
) 
71 
(14.2%) 
5 
(1.0%
) 
160 
(32.1
%) 
         
Gastrointestinal 
disorders* 24 (4.5%) 
11 
(2.1%) 
1 
(0.2
%) 
36 
(6.8%) 
21 
(4.2%) 
12 
(2.4%) 
1 
(0.2%
) 
34 
(6.8%
) 
         
Urinary tract infection 16 
(3.0%) 
11 
(2.1%) 
1 
(0.2
%) 
28 
(5.3%) 
15 
(3.0%) 
10 
(2.0%) 
0 
(0.0%
) 
25 
(5.0%
) 
         
Procedural pain 13 
(2.4%) 
15 
(2.8%) 
0 
(0.0
%) 
28 
(5.3%) 
13 
(2.6%) 
7 
(1.4%) 
0 
(0.0%
) 
20 
(4.0%
) 
         
Renal and urinary 
disorders** 
63 
(11.8%
) 
62 
(11.6%) 
12 
(2.3
%) 
137 
(25.7%
) 
61 
(12.2%
) 
52 
(10.4%) 
4 
(0.8%
) 
117 
(23.4
%) 
 
* Including abdominal pain, constipation, diarrhea, nausea and vomiting 
 
**  including bladder pain, bladder perforation, bladder spasm, dysuria, 
hematuria, micturition urgency, pollakiuria and urinary retention  
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Table 5 Summary of most frequent AEs in group 2 
 
Group 2* 
HAL, N = 791 
MedDRA Body System 
Preferred Term 
Mild 
n (%) 
Moderate 
n (%) 
Severe 
n (%) 
Sum 
n (%) 
Total number of unique 
AEs occurring in at least 
1% of the safety set 
across studies 
483 271 28 782 
Patients with at least 
one AE  211 (26.7%) 
161 
(20.4%) 
26 
(3.3%) 398 (50.3%) 
     
Gastrointestinal 
disorders* 56 (7.1%) 
36 
(4.6%) 2 (0.3%) 94 (11.9%) 
     
Urinary tract infection 12 (1.5%) 9 (1.1%) 1 (0.1%) 22 (2.8%) 
     
Procedural pain 59 (7.5%) 34 (4.3%) 1 (0.1%) 94 (11.9%) 
     
Renal and urinary 
disorders** 158 (20.0%) 91 (11.5%) 
17 
(2.1%) 266 (33.6%) 
 
* Including abdominal pain, constipation, diarrhea, nausea and vomiting 
 
**  including bladder pain, bladder perforation, bladder spasm, dysuria, 
hematuria, micturition urgency, pollakiuria and urinary retention  
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Table 6: HAL mean retention times 
 
Study 
[reference] 
Mean retention time in minutes (min 
and max) Patient number 
B201/00 [5] 86.2 (45-229) 52 
B301/01 [6] 85.7 (5-343) 278 
B302/01 [7,8] 87.0 (34-210) 297 
B303/01 [9] 82.4 (10-360) 162 
B304/04 [4] 102.7 (12-303) 109 
B305/04 [3] 90.3 (4-255) 410 
 
 
